Literature DB >> 10211099

Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.

C A Schmitt1, W Schwaeble, B M Wittig, K H Meyer zum Büschenfelde, W G Dippold.   

Abstract

The membrane-bound complement inhibitors CD46 (membrane cofactor protein), CD55 (decay-accelerating factor) and CD59 (protectin) protect tumour cells against lysis by activated complement. In this study, a total of 14 (3 gastric, 3 colonic and 8 pancreatic) gastrointestinal tumour cell lines were examined for the expression of CD46, CD55 and CD59 with respect to the regulatory efficacy of interferon-gamma (IFN-gamma). The effects of IFN-gamma on mRNA and protein expression levels of CD46, CD55 and CD59 were evaluated by Northern blot hybridisation, RT-PCR, flow cytometry and immunostaining. In unstimulated cell lines, CD46 and CD59 transcripts were expressed at comparable levels, whereas the basal expression of CD55 mRNA was heterogeneous. The complement inhibitor proteins were detected in all cell lines using specific antibodies. Additional immunohistochemical stainings of gastrointestinal tissue specimens supported these findings. IFN-gamma evoked a weak induction of certain transcripts in a subset of the cell lines. Upregulation of protein expression was only observed in HT29 cells for CD55 and CD59 and was accompanied by a marked increase of the corresponding transcripts. We conclude that membrane-bound complement inhibitors are broadly expressed in gastrointestinal tumour cells and vary in their susceptibility to IFN-gamma. Thus, they may be involved in tumour escape mechanisms in gastric, pancreatic and colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211099     DOI: 10.1016/s0959-8049(98)00290-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  Use of preferentially replicating bacteria for the treatment of cancer.

Authors:  M Sznol; S L Lin; D Bermudes; L M Zheng; I King
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  CD55 expression patterns on intestinal neuronal tissue are divergent from the brain.

Authors:  K A Gelderman; H J M A A Zijlmans; M J Vonk; A Gorter
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

Review 3.  Association of Blood Group Antigen CD59 with Disease.

Authors:  Christof Weinstock
Journal:  Transfus Med Hemother       Date:  2022-01-13       Impact factor: 3.747

4.  Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.

Authors:  Jianhui Zhu; Song Nie; Jing Wu; David M Lubman
Journal:  J Proteome Res       Date:  2013-05-29       Impact factor: 4.466

5.  Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.

Authors:  Juan C Varela; Masaki Imai; Carl Atkinson; Rieko Ohta; Michelle Rapisardo; Stephen Tomlinson
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

6.  Afa/Dr diffusely adhering Escherichia coli infection in T84 cell monolayers induces increased neutrophil transepithelial migration, which in turn promotes cytokine-dependent upregulation of decay-accelerating factor (CD55), the receptor for Afa/Dr adhesins.

Authors:  Fréderic Bétis; Patrick Brest; Véronique Hofman; Julie Guignot; Imad Kansau; Bernard Rossi; Alain Servin; Paul Hofman
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 7.  Complement in Pancreatic Disease-Perpetrator or Savior?

Authors:  Lucas Bettac; Stephanie Denk; Thomas Seufferlein; Markus Huber-Lang
Journal:  Front Immunol       Date:  2017-01-17       Impact factor: 7.561

8.  Decreased expression levels of complement regulator CD55 contribute to the development of bullous pemphigoid.

Authors:  Pei Qiao; Er-Le Dang; Hui Fang; Jie-Yu Zhang; Bing Li; Sheng-Xian Shen; Yi-Xin Luo; Jie Lei; Shuai Shao; Hong-Jiang Qiao; Gang Wang
Journal:  Oncotarget       Date:  2017-09-23

9.  Identification of DDX31 as a Potential Oncogene of Invasive Metastasis and Proliferation in PDAC.

Authors:  Yongjie Xie; Yang Liu; Jinsheng Ding; Guangming Li; Bo Ni; Huifang Pang; Xin Hu; Liangliang Wu
Journal:  Front Cell Dev Biol       Date:  2022-02-14

Review 10.  Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.

Authors:  Li-Chung Tsao; Jeremy Force; Zachary C Hartman
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 13.312

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.